Log in

Manitex Capital Stock Price, News & Analysis (CVE:MNX)

Today's Range N/A
50-Day Range
MA: C$0.21
52-Week Range N/A
Volume5,000 shs
Average Volume18,029 shs
Market CapitalizationC$2.76 million
P/E RatioN/A
Dividend YieldN/A
Manitex Capital Inc., through its subsidiary, Valeo Pharma Inc., acquires and markets specialty pharmaceutical products, and distributes third-party pharmaceutical products primarily in Canada. It operates through two segments, Investments and Pharmaceutical. The company sells its products through wholesalers and retail pharmacy chains, as well as through hospitals and other groups. It also invests in marketable securities, as well as provides consulting services for private companies. Manitex Capital Inc. is headquartered in Kirkland, Canada.

Industry, Sector and Symbol

Industry Medical Distribution



Sales & Book Value

Annual SalesC$4.38 million
Book ValueC$1.42 per share



Market CapC$2.76 million
Next Earnings DateN/A
OptionableNot Optionable

Receive MNX News and Ratings via Email

Sign-up to receive the latest news and ratings for MNX and its competitors with MarketBeat's FREE daily newsletter.

Manitex Capital (CVE:MNX) Frequently Asked Questions

What is Manitex Capital's stock symbol?

Manitex Capital trades on the Canadian Venture Exchange (CVE) under the ticker symbol "MNX."

Has Manitex Capital been receiving favorable news coverage?

Press coverage about MNX stock has trended somewhat negative recently, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Manitex Capital earned a coverage optimism score of -1.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Manitex Capital.

Who are some of Manitex Capital's key competitors?

Who are Manitex Capital's key executives?

Manitex Capital's management team includes the folowing people:
  • Mr. Steven Saviuk, Chairman, Pres & CEO (Age 60)
  • Ms. Helen Saviuk, CFO & Director
  • Mr. Ronald S. Perry CA, CPA, Sec. & Independent Director (Age 63)
  • Mr. Marc Leger, Exec. VP of Commercial Operations - Valeo Pharma Inc
  • Nathalie Therrien, Vice-Pres of QA & Regulatory Affairs - Valeo Pharma Inc.

How do I buy shares of Manitex Capital?

Shares of MNX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

How big of a company is Manitex Capital?

Manitex Capital has a market capitalization of C$0.00 and generates C$4.38 million in revenue each year. View Additional Information About Manitex Capital.

How can I contact Manitex Capital?

The company can be reached via phone at 514-693-8844.

MarketBeat Community Rating for Manitex Capital (CVE MNX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  9 (Vote Outperform)
Underperform Votes:  8 (Vote Underperform)
Total Votes:  17
MarketBeat's community ratings are surveys of what our community members think about Manitex Capital and other stocks. Vote "Outperform" if you believe MNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Featured Article: 52 Week Highs

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel